The contract with the pharmaceutical company remains in force and we expect the company to supply sufficient doses of the vaccine, according to the established schedule, an official of the regional bloc confirmed to the press here.
Hours ago, the EMA and the World Health Organization (WHO) reported that there is no evidence to confirm the relationship between blood clots in some immunized patients and the application of the vaccine.
It is just known most of the cases recorded correspond to women under 60 years old, and occurred in the two weeks following vaccination, the source added, setting out that there is still an ongoing investigation.
In March, scientific alarms were raised about side effects in patients inoculated with AstraZeneca’s drug in the EU.
A man died in Austria 10 days after being vaccinated, victim of multiple thrombosis, and later another person was hospitalized for pulmonary thromboembolism after being immunized.
However, the EMA reported that its experts did not confirm that the use of the immunizer increased the risk of such complications and recommended its continued use.
The WHO subscribed to this request under the argument that the benefits outweighed the risks, while other countries of the known old continent suspended the drug, later reconsidering their decision.